MAbs

PreclinicalSmall molecule

IIRCCS National Neurological Institute "C. Mondino" Foundation

MAbs is one of 32 small molecule programs targeting Migraine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MigraineActive, not recruiting

MigrainePreclinical

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Vyepti

Lundbeck

Preclinical

12 2

Savella

AbbVie

Preclinical

2 3

Botox

RRevance Therapeutics, Inc.

Preclinical

9 4

Cervidil

Pfizer

Preclinical

1 5

Adempas

Bayer

Preclinical

1 6

Viagra

VViatris Specialty LLC

Preclinical

2 7

Nitrostat

VViatris Specialty LLC

Preclinical

2 8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Pristiq

PPrism Pharmaceuticals

Preclinical

1 10

Botulinum Toxin a

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Migraine2 trials

Searching for Novel Biological Phenotypes in Migraine Patients Resistant to Treatments

Recruiting·IIRCCS National Neurological Institute "C. Mondino" Foundation··NCT06562413·100 enrolled

Biochemical Profiling of Migraine Patients

Recruiting·IIRCCS National Neurological Institute "C. Mondino" Foundation··NCT06549270·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MAbs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MAbs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MAbs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IRCCS National Neurological Institute "C. Mondino" Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIRCCS National Neurological Institute "C. Mondino" Foundation

MAbs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Migraine2 trials

References

Drug Info

Quick Facts

Related News